Wed Oct 12, 2005 8:23 pm   Reply with quote      

An additional 20 patients with ovarian cancer have been included in a clinical trial at Austin Hospital in Melbourne.

The trial is testing the effectiveness of a vaccine, administered to women already diagnosed with ovarian cancer.

The treatment is made by mixing patients’ cells with a vaccine that kills proteins on ovarian cancer tumours.

Spokesperson for the company developing the vaccine, Marcus Clark, says if the therapeutic vaccine works it will save lives.

“The survival rate for advanced cancer at five years is less than 20 per cent,” he said.

“So there is clearly a need for a therapy that can really improve outcomes for women but also take away the side-effects of chemo.

“There is a real need for therapy for ovarian cancer.”

Aaron

Wed Oct 12, 2005 9:22 pm   Reply with quote      

How many people die from Ovarian cancer every year?

Thu Oct 13, 2005 9:35 pm   Reply with quote      

I'm not sure exactly but ovarian cancer is apparently responsible for 5% of all cancer deaths among women.

Aaron

Thu Oct 13, 2005 10:01 pm   Reply with quote      

Causes

Ovarian cancer is the fourth leading cause of cancer death in women, the leading cause of death from gynecologic malignancies and the second most commonly diagnosed gynecologic malignancy. It is idiopathic, meaning that the exact cause is unknown. The disease is more common in industrialized nations, with the exception of Japan. In the United States, females have a 1.4 percent to 2.5 percent (1 out of 40-60 women) lifelong chance of developing ovarian cancer.

Older women are at highest risk. More than half of the deaths from ovarian cancer occur in women between 55 and 74 years of age and approximately one quarter of ovarian cancer deaths occur in women between 35 and 54 years of age.

The risk for developing ovarian cancer appears to be affected by several factors. The more children a woman has, the lower her risk of ovarian cancer. Early age at first pregnancy, older ages of final pregnancy, and the use of some oral contraceptive pills have also been shown to have a protective effect. Ovarian cancer is reduced in women after tubal legation.

The link to the use of fertility medication has been controversial. An analysis in 1991 raised the possibility that use of drugs that stimulate ovulation may increase the risk for ovarian cancer. Several cohort studies and case-control studies have been conducted since then without providing conclusive evidence for such a link with the possible exception that prolonged use (> 1 year) of clomiphene citrate should be avoided. It will remain a complex topic to study as the infertile population differs in parity from the "normal" population.

There is good evidence that in some women genetic factors are important. Carrier of certain mutations of the BRCA1 or the BRCA2 gene are at higher risk of both breast cancer and ovarian cancer, often at an earlier age than the general population. Patients with a personal history of breast cancer, or a family history of breast and/or ovarian cancer, may have an elevated risk. A strong family history of uterine, colon, or other gastrointestinal cancers may indicate the presence of a syndrome known as hereditary non-polyposis colon cancer (HNPCC), which confers a higher risk for developing ovarian cancer. Patients with strong genetic risk for ovarian cancer may consider the use of prophylactic oophorectomy after completion of child-bearing.

Other factors that have been investigated, such as talc use, asbestos exposure, high dietary fat content, and childhood mumps infection, are controversial and have not been definitively proven.

A study funded by American Cancer Society conducted at the H. Lee Moffitt Cancer Center of the University of South Florida has found a correlation between high levels of lysophospholipids (a type of fatty acid) with ovarian cancer patients and low levels of lysophospholipids with healthy women. This potential biomarker can be detected by a simple blood test. The blood test was 93 percent accurate as predictor of ovarian cancer with less than 4 percent false positives of the 117 women studied. Other indicators of ovarian cancer could be used to increase accuracy to 100 percent.

The document was originally published at Wikipedia and the document is licensed under GNU Free Document License. If you'd like to find out more about Ovarian_cancer, you might be interested in visiting this page in Wikipedia.